Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains? [Yahoo! Finance]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Yahoo! Finance
The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 12.3% gain over the past four weeks. The sudden price rise can be attributed to growing investors' optimism surrounding the company's promising pipeline. Last month, the FDA granted orphan drug designation to Beam Therapeutics' investigational genome-editing candidate, BEAM-101, for treating sickle cell disease, an inherited blood disorder. BEAM-101 showed efficacy in increasing fetal hemoglobin and reducing sickle hemoglobin in early trials. This company is expected to post quarterly loss of $1.04 per share in its upcoming report, which represents a year-over-year change of +6.3%. Revenues are expected to be $13.79 million, up 17.1% from the year-ago quarter. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat ConditionsPR Newswire
- Beam Therapeutics (BEAM) Is Up 6.9% After New BEACON Trial Data Spotlight Base-Editing Potential [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual MeetingGlobeNewswire
BEAM
Earnings
- 11/4/25 - Miss
BEAM
Sec Filings
- 12/11/25 - Form 8-K
- 11/5/25 - Form SCHEDULE
- 11/4/25 - Form 10-Q
- BEAM's page on the SEC website